Thorac Cardiovasc Surg 2015; 63(03): 217-222
DOI: 10.1055/s-0035-1544210
Original Thoracic
Georg Thieme Verlag KG Stuttgart · New York

Extended Thymectomy Including Lung-Sparing Pleurectomy for the Treatment of Thymic Malignancies with Pleural Spread

Servet Bölükbas
1   Department of Thoracic Surgery, Helios-Klinikum Wuppertal, University Hospital Witten/Herdecke, Wuppertal, Germany
,
Michael Eberlein
2   Division of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, Iowa, United States
,
Selma Oguzhan
3   Department of Thoracic Surgery, Dr. Horst Schmidt Klinik, Wiesbaden, Germany
,
Moritz Schirren
3   Department of Thoracic Surgery, Dr. Horst Schmidt Klinik, Wiesbaden, Germany
,
Stefan Sponholz
3   Department of Thoracic Surgery, Dr. Horst Schmidt Klinik, Wiesbaden, Germany
,
Joachim Schirren
3   Department of Thoracic Surgery, Dr. Horst Schmidt Klinik, Wiesbaden, Germany
› Author Affiliations
Further Information

Publication History

02 June 2014

01 December 2014

Publication Date:
26 March 2015 (online)

Abstract

Objective To investigate the outcome of extended thymectomy including lung-sparing pleurectomy (extended surgery) in primary clinically advanced Masaoka-Koga stage IVa thymic malignancies.

Patients and Methods Thirteen patients diagnosed with thymic malignancies at primary clinically Masaoka-Koga stage IVa were retrospectively analyzed between January 2000 and December 2012 at the Department of Thoracic Surgery, Dr. Horst Schmidt Klinik, Wiesbaden. Chi-square tests, Kaplan-Meier analyses, log-rank tests, and Cox regression analyses were used to estimate survival and determine prognosticators of survival.

Results World Health Organization (WHO) classification were type C (n = 6), type B3 (n = 5), and type AB (n = 2), respectively. Nine patients underwent extended surgery. Morbidity was observed in three patients (33%). Mortality occurred in one patient. Four patients (31%) were unresectable at the time of surgery and underwent chemoradiation. Despite the clinically staging, five patients had lymph node metastases and thus pathologic Masaoka-Koga stage IVb. Median survival (MS) for all patients was 49 months. Extended surgery (MS 89 months) was associated with prolonged survival compared with patients who underwent only chemoradiation (MS 5 months). Stage migration due to lymph node metastases, WHO-classification type C, and T3/4-status were associated with inferior survival in the univariate analysis. Extended surgery remained the only independent significant prognosticator in the multivariate analysis.

Conclusion Extended surgery within multimodality treatments might offer survival advantage for advanced thymic malignancies with pleural spread. Patients with lymph node metastases and WHO classification type C might be at high risk of unresectability.

Note

This article was presented in part at the 19th European Conference on General Thoracic Surgery June 5–8, 2011, Marseille (France); 20th Conference on German Society of General Thoracic Surgery (DGT), September 22–24, 2011, Düsseldorf-Kaiserswerth (Germany); and 129th Conference of the German Society of Surgery (DGCH), April 24–27, 2012, Berlin (Germany).


 
  • References

  • 1 Detterbeck FC, Zeeshan A. Thymoma: current diagnosis and treatment. Chin Med J (Engl) 2013; 126 (11) 2186-2191
  • 2 Kondo K, Monden Y. Lymphogenous and hematogenous metastasis of thymic epithelial tumors. Ann Thorac Surg 2003; 76 (6) 1859-1864 , discussion 1864–1865
  • 3 Kondo K. Tumor-node metastasis staging system for thymic epithelial tumors. J Thorac Oncol 2010; 5 (10) (Suppl. 04) S352-S356
  • 4 Detterbeck F, Parsons A. Thymic tumors: a review of current diagnosis, classification, and treatment. In: Patterson GA, Deslauriers J, Lerut A, Luketich JD, Rice TW, Pearson FG, , eds. Thoracic and Esophageal Surgery. 3rd ed. Philadelphia, PA: Elsevier; 2008: 1589-1614
  • 5 Huang J, Rizk NP, Travis WD , et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 2007; 134 (6) 1477-1483 , discussion 1483–1484
  • 6 Fabre D, Fadel E, Mussot S , et al. Long-term outcome of pleuropneumonectomy for Masaoka stage IVa thymoma. Eur J Cardiothorac Surg 2011; 39 (5) e133-e138
  • 7 Therasse P, Arbuck SG, Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3) 205-216
  • 8 Bölükbas S, Eberlein M, Schirren J. Video-atlas of radical pleurectomy for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012; 1 (4) 534-536
  • 9 Blumberg D, Burt ME, Bains MS , et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998; 115 (2) 303-308 , discussion 308–309
  • 10 Lardinois D, De Leyn P, Van Schil P , et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006; 30 (5) 787-792
  • 11 Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics 2004; 24 (6) 1611-1616
  • 12 Endo M, Nakagawa K, Ohde Y , et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008; 61 (3) 350-355
  • 13 Rimner A, Gomez DR, Wu AJ , et al. Failure patterns relative to radiation treatment fields for stage II-IV thymoma. J Thorac Oncol 2014; 9 (3) 403-409
  • 14 Moser B, Scharitzer M, Hacker S , et al. Thymomas and thymic carcinomas: prognostic factors and multimodal management. Thorac Cardiovasc Surg 2014; 62 (2) 153-160
  • 15 Lucchi M, Ambrogi MC, Duranti L , et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 2005; 79 (6) 1840-1844
  • 16 Curran Jr WJ, Kornstein MJ, Brooks JJ, Turrisi III AT. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 1988; 6 (11) 1722-1727
  • 17 Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg 2006; 81 (6) 2328-2334
  • 18 Ried M, Guth H, Potzger T , et al. Surgical resection of thymoma still represents the first choice of treatment. Thorac Cardiovasc Surg 2012; 60 (2) 145-149
  • 19 Ried M, Potzger T, Sziklavari Z , et al. Extended surgical resections of advanced thymoma Masaoka stages III and IVa facilitate outcome. Thorac Cardiovasc Surg 2014; 62 (2) 161-168
  • 20 Ruffini E, Van Raemdonck D, Detterbeck F, Rocco G, Thomas P, Venuta F ; European Society of Thoracic Surgeons Thymic Questionnaire Working Group. Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. J Thorac Oncol 2011; 6 (3) 614-623
  • 21 Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA thymoma. Ann Thorac Surg 2006; 82 (4) 1234-1239
  • 22 Yang HC, Yoon YS, Kim HK , et al. En bloc extended total thymectomy and extrapleural pneumonectomy in Masaoka stage IVA thymomas. J Cardiothorac Surg 2011; 6: 28
  • 23 Ried M, Neu R, Schalke B, Sziklavari Z, Hofmann HS. Radical pleurectomy and hyperthermic intrathoracic chemotherapy for treatment of thymoma with pleural spread [in German]. Zentralbl Chir 2013; 138 (Suppl. 01) S52-S57
  • 24 Okumura M, Ohta M, Tateyama H , et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94 (3) 624-632
  • 25 Maggi G, Giaccone G, Donadio M , et al. Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer 1986; 58 (3) 765-776
  • 26 Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004; 77 (5) 1860-1869
  • 27 Kondo K, Yoshizawa K, Tsuyuguchi M , et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 2004; 77 (4) 1183-1188